{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:11:59Z","timestamp":1782587519337,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovationsfonden,Denmark","award":["0153-00086B"],"award-info":[{"award-number":["0153-00086B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rheumatic joints have an altered cartilage turnover. Cartilage intermediate layer protein 1 (CILP-1) is secreted from articular chondrocytes and deposited into the cartilage extracellular matrix. We developed an immunoassay targeting a Matrix Metalloproteinase (MMP)-generated neo-epitope of CILP-1, named CILP-M. Human articular cartilage was cleaved with proteolytic enzymes and CILP-M levels were measured. We also quantified CILP-M in two studies from patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and osteoarthritis (OA) and explored the monitoring and prognostic potential of CILP-M in TNF-\u03b1 inhibitory treatment and modified Stoke AS Spine Score (mSASSS) progression. CILP-M was generated by MMP-1, -8 and -12. In the discovery study, CILP-M was significantly higher in patients with RA, AS and OA than healthy donors (p\u2009&lt;\u20090.01, p\u2009&lt;\u20090.001, p\u2009&lt;\u20090.05) with an area under the curve (AUC) between the diseased groups and healthy donors &gt;\u20090.95 (p\u2009&lt;\u20090.001). In the validation study, patients with RA and AS had significantly higher CILP-M levels than healthy controls (p\u2009&lt;\u20090.001) and AUC\u2009&gt;\u20090.90 (p\u2009&lt;\u20090.001). Patients with AS treated with TNF- \u03b1 inhibitory treatment in the validation study had significantly lower CILP-M levels after treatment (p\u2009=\u20090.004). CILP-M may provide useful insights into cartilage degradation processes in rheumatic diseases.<\/jats:p>","DOI":"10.1038\/s41598-023-48787-x","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:02:14Z","timestamp":1702033334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A novel biomarker of MMP-cleaved cartilage intermediate layer protein-1 is elevated in patients with rheumatoid arthritis, ankylosing spondylitis and osteoarthritis"],"prefix":"10.1038","volume":"13","author":[{"given":"Helena","family":"Port","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie M\u00f8ller","family":"Hausgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wichuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovile","family":"Sinkeviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Holm Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"48787_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/1941738109350438","volume":"1","author":"AJ Sophia Fox","year":"2009","unstructured":"Sophia Fox, A. J., Bedi, A. & Rodeo, S. A. The basic science of articular cartilage: Structure, composition, and function. Sports Health 1, 461\u2013468 (2009).","journal-title":"Sports Health"},{"key":"48787_CR2","doi-asserted-by":"publisher","unstructured":"Lorenzo, P., Bayliss, M. T. & Heineg\u00e5rd, D. A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age*. (1998). https:\/\/doi.org\/10.1074\/jbc.273.36.23463.","DOI":"10.1074\/jbc.273.36.23463"},{"key":"48787_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/ar2592","volume":"11","author":"MB Goldring","year":"2009","unstructured":"Goldring, M. B. & Marcu, K. B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 11, 224 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"48787_CR4","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/art.23654","volume":"58","author":"EY Zhen","year":"2008","unstructured":"Zhen, E. Y. et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum. 58, 2420\u20132431 (2008).","journal-title":"Arthritis Rheum."},{"key":"48787_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.matbio.2004.07.007","volume":"23","author":"P Lorenzo","year":"2004","unstructured":"Lorenzo, P., Bayliss, M. T. & Heineg\u00e5rd, D. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biol. 23, 381\u2013391 (2004).","journal-title":"Matrix Biol."},{"key":"48787_CR6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/art.20443","volume":"50","author":"AM Valdes","year":"2004","unstructured":"Valdes, A. M. et al. Association study of candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 50, 2497\u20132507 (2004).","journal-title":"Arthritis Rheum."},{"key":"48787_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/art.21621","volume":"54","author":"AM Valdes","year":"2006","unstructured":"Valdes, A. M. et al. Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum. 54, 533\u2013539 (2006).","journal-title":"Arthritis Rheum."},{"key":"48787_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.924692","volume":"10","author":"P Bermudez-Lekerika","year":"2022","unstructured":"Bermudez-Lekerika, P. et al. Immuno-modulatory effects of intervertebral disc cells. Front. Cell Dev. Biol. 10, 1\u201332 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"48787_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng1557","volume":"37","author":"S Seki","year":"2005","unstructured":"Seki, S. et al. A functional SNP in CILP, encoding cartilage intermediate layer protein, is associated with susceptibility to lumbar disc disease. Nat. Genet. 37, 607\u2013612 (2005).","journal-title":"Nat. Genet."},{"key":"48787_CR10","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1177\/0363546510376714","volume":"38","author":"SK Min","year":"2010","unstructured":"Min, S. K. et al. Cartilage intermediate layer protein gene is associated with lumbar disc degeneration in male, but not female, collegiate athletes. Am. J. Sports Med. 38, 2552\u20132557 (2010).","journal-title":"Am. J. Sports Med."},{"key":"48787_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2350-12-153","volume":"12","author":"A Kelempisioti","year":"2011","unstructured":"Kelempisioti, A. et al. Genetic susceptibility of intervertebral disc degeneration among young Finnish adults. BMC Med. Genet. 12, 153 (2011).","journal-title":"BMC Med. Genet."},{"key":"48787_CR12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/1529-0131(200104)44:4<838::AID-ANR140>3.0.CO;2-C","volume":"44","author":"J-I Tsuruha","year":"2001","unstructured":"Tsuruha, J.-I. et al. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 44, 838\u2013845 (2001).","journal-title":"Arthritis Rheum."},{"key":"48787_CR13","doi-asserted-by":"publisher","first-page":"PP15","DOI":"10.1530\/boneabs.1.PP15","volume":"1","author":"I Kerna","year":"2013","unstructured":"Kerna, I., Kisand, K., Tamm, A. & Tamm, A. Cartilage intermediate layer protein is produced in synovial membrane of osteoarthritic joint and upregulated in osteoarthritis associated fibrosis. Bone Abstr. 1, PP15. https:\/\/doi.org\/10.1530\/boneabs.1.PP15 (2013).","journal-title":"Bone Abstr."},{"key":"48787_CR14","unstructured":"CILP\u2014Cartilage intermediate layer protein 1\u2014Homo sapiens (Human)|UniProtKB|UniProt. https:\/\/www.uniprot.org\/uniprotkb\/O75339\/entry."},{"key":"48787_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18208-y","volume":"11","author":"DR Park","year":"2020","unstructured":"Park, D. R. et al. Osteoclast-associated receptor blockade prevents articular cartilage destruction via chondrocyte apoptosis regulation. Nat. Commun. 11, 1\u201311 (2020).","journal-title":"Nat. Commun."},{"key":"48787_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0675-5","volume":"17","author":"J Bleil","year":"2015","unstructured":"Bleil, J. et al. Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: Implications for joint remodeling in AS. Arthritis Res. Ther. 17, 1\u201310 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"48787_CR17","doi-asserted-by":"publisher","unstructured":"Rannou, F., Fran\u00e7ois, M., Corvol, M.-T. & Berenbaum, F. Cartilage breakdown in rheumatoid arthritis. (2005). https:\/\/doi.org\/10.1016\/j.jbspin.2004.12.013.","DOI":"10.1016\/j.jbspin.2004.12.013"},{"key":"48787_CR18","doi-asserted-by":"publisher","unstructured":"Mehana, E.-S. E., Khafaga, A. F. & El-Blehi, S. S. The role of matrix metalloproteinases in osteoarthritis pathogenesis: An updated review. (2019). https:\/\/doi.org\/10.1016\/j.lfs.2019.116786.","DOI":"10.1016\/j.lfs.2019.116786"},{"key":"48787_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5114\/pdia.2012.31493","volume":"29","author":"A Kuz\u1e3fi\u0144ski","year":"2012","unstructured":"Kuz\u1e3fi\u0144ski, A., Przybyszewski, M., Graczyk, M. & Bartuzi, Z. The role of extracellular matrix metalloproteinases and their inhibitors in allergic diseases. Postep. Dermatologii i Alergol. 29, 384\u2013389 (2012).","journal-title":"Postep. Dermatologii i Alergol."},{"key":"48787_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cytogfr.2006.04.001","volume":"17","author":"P Van Lint","year":"2006","unstructured":"Van Lint, P. & Libert, C. Matrix metalloproteinase-8: Cleavage can be decisive. Cytokine Growth Factor Rev. 17, 217\u2013223 (2006).","journal-title":"Cytokine Growth Factor Rev."},{"key":"48787_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0002-9440(10)63368-8","volume":"165","author":"YE Chen","year":"2004","unstructured":"Chen, Y. E. MMP-12, an old enzyme plays a new role in the pathogenesis of rheumatoid arthritis?. Am. J. Pathol. 165, 1069 (2004).","journal-title":"Am. J. Pathol."},{"key":"48787_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0002-9440(10)63395-0","volume":"165","author":"X Wang","year":"2004","unstructured":"Wang, X. et al. Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. Am. J. Pathol. 165, 1375 (2004).","journal-title":"Am. J. Pathol."},{"key":"48787_CR23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1074\/mcp.RA119.001554","volume":"18","author":"P Fern\u00e1ndez-Puente","year":"2019","unstructured":"Fern\u00e1ndez-Puente, P. et al. Analysis of endogenous peptides released from osteoarthritic cartilage unravels novel pathogenic markers. Mol. Cell. Proteom. 18, 2018\u20132028 (2019).","journal-title":"Mol. Cell. Proteom."},{"key":"48787_CR24","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1021\/pr501024p","volume":"13","author":"L Lourido","year":"2014","unstructured":"Lourido, L. et al. Quantitative proteomic profiling of human articular cartilage degradation in osteoarthritis. J. Proteome Res. 13, 6096\u20136106 (2014).","journal-title":"J. Proteome Res."},{"key":"48787_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47502-z","volume":"9","author":"M Hu\u0161\u00e1kov\u00e1","year":"2019","unstructured":"Hu\u0161\u00e1kov\u00e1, M. et al. Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. Sci. Rep. 9, 1\u201310 (2019).","journal-title":"Sci. Rep."},{"key":"48787_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fimmu.2019.00305","volume":"10","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych, W. P. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front. Immunol. 10, 305 (2019).","journal-title":"Front. Immunol."},{"key":"48787_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-16201-y","volume":"7","author":"FA Van Nieuwenhoven","year":"2017","unstructured":"Van Nieuwenhoven, F. A. et al. Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. Sci. Rep. 7, 1\u20139 (2017).","journal-title":"Sci. Rep."},{"key":"48787_CR28","doi-asserted-by":"publisher","unstructured":"Keranov, S. et al. CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. https:\/\/doi.org\/10.1183\/13993003.01192-2019.","DOI":"10.1183\/13993003.01192-2019"},{"key":"48787_CR29","doi-asserted-by":"publisher","unstructured":"Zhang, C.-L. et al. Cartilage intermediate layer protein-1 alleviates pressure overload-induced cardiac fibrosis via interfering TGF-\u03b21 signaling. (2018). https:\/\/doi.org\/10.1016\/j.yjmcc.2018.02.006.","DOI":"10.1016\/j.yjmcc.2018.02.006"},{"key":"48787_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/rheumatology\/ken148","volume":"47","author":"D Vosse","year":"2008","unstructured":"Vosse, D. et al. Association of markers of bone-and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford). 47, 1219\u20131222 (2008).","journal-title":"Rheumatology (Oxford)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48787-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:13:12Z","timestamp":1702033992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48787"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48787-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HP, CMH, YH, DS, ACBJ and SHN are full-time employees at Nordic Bioscience A\/S. YH, DS, ACBJ and SHN, hold stocks in Nordic Bioscience A\/S. WPM has received consulting fees from AbbVie, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and grant\/research support from AbbVie, Novartis, Pfizer, and UCB; and is Chief Medical Officer of CARE Arthritis Limited. SW has no competing interest to declare. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21717"}}